VISIOGENE

Visiogene is preclinical biotechnology startup developing gene therapies for blindness

We are leveraging our patented technologies of retinal penetrating Adeno-Associated Viruses (AAV-IKV)  that can deliver genes to the outer retina via an intravitreal injection and a novel chaperone known as Nuc1 that can deliver proteins into retinal cells in vivo

Retinal Penetrating Adeno-Associated Virus PMID: 39172462

Cell-Penetrating Chaperone Nuc1 for Small- and Large-Molecule Delivery Into Retinal Cells and Tissues PMID: 39028980